Home / Going-concern warnings / ImmunityBio, Inc.

3/5ImmunityBio, Inc. (IBRX): Going-concern doubt

Filed 2026-05-07 路 Form 10-Q 路 Accession 0001326110-26-000059 mid

Market data

Price before filing: $8.38 (2026-05-06 close, split/dividend-adjusted)
Market cap at flag: $7.97B (2026-05-07) 路 Latest: $9.64B (2026-10-16)

What happened next

WindowIBRXSPYvs SPY
30 days-14.4%+0.7%-15.2%2026-06-08
90 days-13.5%+5.2%-18.7%2026-08-05
180 dayspendingpendinguntil 2026-11-03
1 yearpendingpendinguntil 2027-05-07

Return from the last close before the filing date to the first close on/after the window end. Pending windows have not fully elapsed. Past performance says nothing certain about the future.

Verified excerpt

"As a result of continuing anticipated operating cash outflows as we commercialize our approved product and accelerate our development efforts, we believe that substantial doubt exists regarding our ability to continue as a going concern without additional funding or financial support."

Quoted from the filing. Source

What this means

The filing states that substantial doubt exists about the company's ability to continue as a going concern: it may not have enough cash to last the next 12 months. Expect dilution, debt deals or worse. An auditor's going-concern paragraph is the strongest form of this warning.

Source: management disclosure in Form 10-Q (period 2026-03-31)

Why this score: quarterly (unaudited) disclosure

Read the original filing on SEC.gov →

Not investment advice. Automated summary; verify against the filing.

Get the weekly "Red Flags" newsletter

The week's most serious auditor changes, restatements, late filings and going-concern warnings, in plain English. Free. Unsubscribe anytime.

Subscribe to the newsletter →
The signup form didn't load here (often an ad or privacy blocker). This opens beehiiv's secure signup page.

Form not showing? Subscribe on beehiiv →

Newsletter delivered by beehiiv. See our privacy policy.